{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T01:08:43Z","timestamp":1779066523273,"version":"3.51.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"MOST | National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1303200"],"award-info":[{"award-number":["2022YFA1303200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"MOST | National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1303201"],"award-info":[{"award-number":["2022YFA1303201"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32330062"],"award-info":[{"award-number":["32330062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31972933"],"award-info":[{"award-number":["31972933"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372669"],"award-info":[{"award-number":["82372669"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32301236"],"award-info":[{"award-number":["32301236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003154"],"award-info":[{"award-number":["82003154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32201215"],"award-info":[{"award-number":["32201215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471498"],"award-info":[{"award-number":["32471498"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32201212"],"award-info":[{"award-number":["32201212"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"STCSM | Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["22XD1420100"],"award-info":[{"award-number":["22XD1420100"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Major Project of Special Development Funds of Zhangjiang National Independent Innovation Demonstration Zone","award":["ZJ2019-ZD-004"],"award-info":[{"award-number":["ZJ2019-ZD-004"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["2023SHZDZX02"],"award-info":[{"award-number":["2023SHZDZX02"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Sailing Program","award":["23YF1402800"],"award-info":[{"award-number":["23YF1402800"]}]},{"name":"the Fudan original research personalized support project, and the China Postdoctoral Science Foundation","award":["2024T170177"],"award-info":[{"award-number":["2024T170177"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunotherapy has revolutionized cancer treatment, yet many patients show non-sensitivity. Here, we collected treatment-na\u00efve samples from 190 esophageal squamous cell carcinoma (ESCC) patients undergoing anti-programmed death 1 (PD1) immunotherapy for proteome, phosphoproteome, and immunohistochemistry (IHC) analysis. Proteome-based stratification of ESCC identifies three proteomic subtypes (G-I-G-III) related to immunotherapy response and different molecular features, revealing that patients with high mitochondrial complex I protein expression show sensitivity to anti-PD1 immunotherapy. High mitochondrial complex I protein expression of ESCC cells or patient-derived organoids increases sensitivity to CD8\u2009+\u2009T cell-mediated killing in the co-culture systems. Phosphoproteomic data analysis reveals YAP1 activation impairs immunotherapy efficacy. Inhibiting YAP1 or increasing mitochondrial complex I levels bolsters immunotherapy effectiveness in ESCC allograft tumors. Finally, we develop a highly accurate predictive model (AUC\u2009\u2265\u20090.90) by the signatures of mitochondrial complex I-mediated anti-tumor immune response and validate it in independent cohorts. This study provides a rich resource for investigating the mechanisms and indicators of immunotherapy in ESCC.<\/jats:p>","DOI":"10.1038\/s44321-026-00413-9","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:13:16Z","timestamp":1775909596000},"page":"1884-1932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy"],"prefix":"10.1038","volume":"18","author":[{"given":"Fahan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-7675","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanxian","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinzhi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-bei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinwen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haohua","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-8873","authenticated-orcid":false,"given":"Sha","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guichao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqiang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-9785","authenticated-orcid":false,"given":"Changsheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8673-3464","authenticated-orcid":false,"given":"Chen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"413_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J et al (2018) Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023\u20131075","journal-title":"Lancet"},{"key":"413_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18:220","journal-title":"Genome Biol"},{"key":"413_CR3","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1074\/mcp.RA119.001540","volume":"18","author":"OA Arshad","year":"2019","unstructured":"Arshad OA, Danna V, Petyuk VA, Piehowski PD, Liu T, Rodland KD, McDermott JE (2019) An integrative analysis of tumor proteomic and phosphoproteomic profiles to examine the relationships between kinase activity and phosphorylation. Mol Cell Proteom 18:S26\u2013S36","journal-title":"Mol Cell Proteom"},{"key":"413_CR4","doi-asserted-by":"crossref","unstructured":"Bai L, Lyu J, Feng J, Qiao X, Qu Y, Yang G, Zhu Y, Liao L, Gao H, Zang A et al (2025) Cancer biomarkers discovered using pan-cancer plasma proteomic profiling. Nat Biomed Eng 10:16\u201338","DOI":"10.1038\/s41551-025-01448-y"},{"key":"413_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24112-w","volume":"12","author":"R Banchereau","year":"2021","unstructured":"Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel 3rdE, Baldwin N et al (2021) Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun 12:3969","journal-title":"Nat Commun"},{"key":"413_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108\u2013U122","journal-title":"Nature"},{"key":"413_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc3246","volume":"12","author":"T Blankenstein","year":"2012","unstructured":"Blankenstein T, Coulie PG, Gilboa E, Jaffee EM (2012) The determinants of tumour immunogenicity. Nat Rev Cancer 12:307\u2013313","journal-title":"Nat Rev Cancer"},{"key":"413_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, Brigham, Women\u2019s H, Broad I, Brown U, Case Western Reserve U, Dana-Farber Cancer I, Duke U","year":"2017","unstructured":"Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, Brigham, Women\u2019s H, Broad I, Brown U, Case Western Reserve U, Dana-Farber Cancer I, Duke U et al (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541:169\u2013175","journal-title":"Nature"},{"key":"413_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17227-z","volume":"11","author":"W Cao","year":"2020","unstructured":"Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H et al (2020) Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nat Commun 11:3675","journal-title":"Nat Commun"},{"key":"413_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","volume":"15","author":"CM Cattaneo","year":"2020","unstructured":"Cattaneo CM, Dijkstra KK, Fanchi LF, Kelderman S, Kaing S, van Rooij N, van den Brink S, Schumacher TN, Voest EE (2020) Tumor organoid-T-cell coculture systems. Nat Protoc 15:15\u201339","journal-title":"Nat Protoc"},{"key":"413_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P et al (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26:566\u2013576","journal-title":"Nat Med"},{"key":"413_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321\u2013330","journal-title":"Nature"},{"key":"413_CR13","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wang D, Li Y, Qi L, Si W, Bo Y, Chen X, Ye Z, Fan H, Liu B et al (2024) Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell 42:1268\u20131285.e1267","journal-title":"Cancer Cell"},{"key":"413_CR14","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol 33:3541\u20133543","journal-title":"J Clin Oncol"},{"key":"413_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","volume":"40","author":"D Chowell","year":"2022","unstructured":"Chowell D, Yoo SK, Valero C, Pastore A, Krishna C, Lee M, Hoen D, Shi H, Kelly DW, Patel N et al (2022) Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol 40:499\u2013506","journal-title":"Nat Biotechnol"},{"issue":"Suppl 16","key":"413_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-S16-S12","volume":"13","author":"J Cox","year":"2012","unstructured":"Cox J, Mann M (2012) 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinforma 13(Suppl 16):S12","journal-title":"BMC Bioinforma"},{"key":"413_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41422-022-00625-x","volume":"32","author":"Y Cui","year":"2022","unstructured":"Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E, Yan T, Lu X, Huang F, Kong P et al (2022) Author Correction: Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res 32:415\u2013416","journal-title":"Cell Res"},{"key":"413_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7:278","journal-title":"J Immunother Cancer"},{"key":"413_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60485-y","volume":"16","author":"Z Demir","year":"2025","unstructured":"Demir Z, Raynaud M, Divard G, Louis K, Truchot A, Niemann M, Ponsirenas R, Aubert O, Del Bello A, Hertig A et al (2025) Impact of HLA evolutionary divergence and donor-recipient molecular mismatches on antibody-mediated rejection of kidney allografts. Nat Commun 16:5692","journal-title":"Nat Commun"},{"key":"413_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/hep.32624","volume":"77","author":"M Deng","year":"2023","unstructured":"Deng M, Ran P, Chen L, Wang Y, Yu Z, Cai K, Feng J, Qin Z, Yin Y, Tan S et al (2023) Proteogenomic characterization of cholangiocarcinoma. Hepatology 77:411\u2013429","journal-title":"Hepatology"},{"key":"413_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey A, Varelas X, Guan KL (2020) Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov 19:480\u2013494","journal-title":"Nat Rev Drug Discov"},{"key":"413_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","volume":"58","author":"AM Di Giacomo","year":"2009","unstructured":"Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297\u20131306","journal-title":"Cancer Immunol Immunother"},{"key":"413_CR23","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S et al (2018) Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174:1586\u20131598.e1512","journal-title":"Cell"},{"key":"413_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2016.07.007","volume":"166","author":"JM Drake","year":"2016","unstructured":"Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE et al (2016) Phosphoproteome integration reveals patient-specific networks in prostate cancer. Cell 166:1041\u20131054","journal-title":"Cell"},{"key":"413_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nbt.3825","volume":"35","author":"J Feng","year":"2017","unstructured":"Feng J, Ding C, Qiu N, Ni X, Zhan D, Liu W, Xia X, Li P, Lu B, Zhao Q et al (2017) Firmiana: towards a one-stop proteomic cloud platform for data processing and analysis. Nat Biotechnol 35:409\u2013412","journal-title":"Nat Biotechnol"},{"key":"413_CR26","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S et al (2018) Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 378:1976\u20131986","journal-title":"N Engl J Med"},{"key":"413_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","volume":"39","author":"Y Fujii","year":"2021","unstructured":"Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y et al (2021) Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell 39:793\u2013809.e798","journal-title":"Cancer Cell"},{"key":"413_CR28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.cell.2019.10.038","volume":"179","author":"Q Gao","year":"2019","unstructured":"Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y et al (2019) Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 179:1240","journal-title":"Cell"},{"key":"413_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux R, Seoighe C (2010) A flexible R package for nonnegative matrix factorization. BMC Bioinforma 11:367","journal-title":"BMC Bioinforma"},{"key":"413_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03121-2","volume":"9","author":"S Ge","year":"2018","unstructured":"Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng J, Yuan J, Chen R, Li Y, Ge Z et al (2018) A proteomic landscape of diffuse-type gastric cancer. Nat Commun 9:1012","journal-title":"Nat Commun"},{"key":"413_CR31","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542\u2013e551","journal-title":"Lancet Oncol"},{"key":"413_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30:582\u2013588","journal-title":"Ann Oncol"},{"key":"413_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma 14:7","journal-title":"BMC Bioinforma"},{"key":"413_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","volume":"179","author":"M Harel","year":"2019","unstructured":"Harel M, Ortenberg R, Varanasi SK, Mangalhara KC, Mardamshina M, Markovits E, Baruch EN, Tripple V, Arama-Chayoth M, Greenberg E et al (2019) Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell 179:236\u2013250.e218","journal-title":"Cell"},{"key":"413_CR35","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/nprot.2016.117","volume":"11","author":"R Herwig","year":"2016","unstructured":"Herwig R, Hardt C, Lienhard M, Kamburov A (2016) Analyzing and interpreting genome data at the network level with ConsensusPathDB. Nat Protoc 11:1889\u20131907","journal-title":"Nat Protoc"},{"key":"413_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35\u201344","journal-title":"Cell"},{"key":"413_CR37","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.1021\/acsomega.4c09289","volume":"10","author":"EM Humphries","year":"2025","unstructured":"Humphries EM, Hains PG, Robinson PJ (2025) Overlap of formalin-fixed paraffin-embedded and fresh-frozen matched tissues for proteomics and phosphoproteomics. ACS Omega 10:6891\u20136900","journal-title":"ACS Omega"},{"key":"413_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","volume":"40","author":"AK Jayavelu","year":"2022","unstructured":"Jayavelu AK, Wolf S, Buettner F, Alexe G, Haupl B, Comoglio F, Schneider C, Doebele C, Fuhrmann DC, Wagner S et al (2022) The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40:301\u2013317.e312","journal-title":"Cancer Cell"},{"key":"413_CR39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","volume":"567","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, Xing B, Sun W, Ren L, Hu B et al (2019) Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 567:257\u2013261","journal-title":"Nature"},{"key":"413_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46785-9","volume":"15","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zheng Y, Zhang YW, Kong S, Dong J, Wang F, Ziman B, Gery S, Hao JJ, Zhou D et al (2024) Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-gamma signaling in squamous cancer. Nat Commun 15:2484","journal-title":"Nat Commun"},{"key":"413_CR41","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.ccell.2025.05.003","volume":"43","author":"JC Knol","year":"2025","unstructured":"Knol JC, Lyu M, Bottger F, Nunes Monteiro M, Pham TV, Rolfs F, Valles-Marti A, Schelfhorst T, de Goeij-de Haas RR, Bijnsdorp IV et al (2025) The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets. Cancer Cell 43:1328\u20131346e.1328","journal-title":"Cancer Cell"},{"key":"413_CR42","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","volume":"183","author":"K Krug","year":"2020","unstructured":"Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, Miles G, Mertins P, Geffen Y, Tang LC et al (2020) Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell 183:1436\u20131456.e1431","journal-title":"Cell"},{"key":"413_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409\u2013413","journal-title":"Science"},{"key":"413_CR44","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s43018-021-00259-9","volume":"2","author":"J Lehtio","year":"2021","unstructured":"Lehtio J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jonsson M et al (2021) Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms. Nat Cancer 2:1224\u20131242","journal-title":"Nat Cancer"},{"key":"413_CR45","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.ccell.2020.08.002","volume":"38","author":"C Li","year":"2020","unstructured":"Li C, Sun YD, Yu GY, Cui JR, Lou Z, Zhang H, Huang Y, Bai CG, Deng LL, Liu P et al (2020) Integrated omics of metastatic colorectal cancer. Cancer Cell 38:734\u2013747.e739","journal-title":"Cancer Cell"},{"key":"413_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-017-0323-6","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Cai S, Liu S, Feng H, Zhang J (2017) Bioinformatics analysis to screen the key prognostic genes in ovarian cancer. J Ovarian Res 10:27","journal-title":"J Ovarian Res"},{"key":"413_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41568-023-00639-6","volume":"24","author":"S Li","year":"2024","unstructured":"Li S, Lu Z, Wu S, Chu T, Li B, Qi F, Zhao Y, Nie G (2024) The dynamic role of platelets in cancer progression and their therapeutic implications. Nat Rev Cancer 24:72\u201387","journal-title":"Nat Rev Cancer"},{"key":"413_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101311","volume":"4","author":"Y Li","year":"2023","unstructured":"Li Y, Wang B, Ma F, Jiang D, Wang Y, Li K, Tan S, Feng J, Wang Y, Qin Z et al (2023) Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies. Cell Rep Med 4:101311","journal-title":"Cell Rep Med"},{"key":"413_CR49","doi-asserted-by":"crossref","unstructured":"Li Y, Xu C, Wang B, Xu FJ, Ma FH, Qu YN, Jiang DX, Li K, Feng JN, Tian S et al (2022) Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nat Commun 13:5723","DOI":"10.1038\/s41467-022-33282-0"},{"key":"413_CR50","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41392-021-00682-5","volume":"6","author":"Y Li","year":"2021","unstructured":"Li Y, Yang B, Ma Y, Peng X, Wang Z, Sheng B, Wei Z, Cui Y, Liu Z (2021) Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma. Signal Transduct Target Ther 6:381","journal-title":"Signal Transduct Target Ther"},{"key":"413_CR51","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C et al (2019) Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med 25:1916\u20131927","journal-title":"Nat Med"},{"key":"413_CR52","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ijc.33976","volume":"151","author":"J Liu","year":"2022","unstructured":"Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z, Li Z, Cui F, Du Z, Zeng Y et al (2022a) Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study. Int J Cancer 151:128\u2013137","journal-title":"Int J Cancer"},{"key":"413_CR53","doi-asserted-by":"crossref","unstructured":"Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, Zhu L, Shen Y, Zhang H, Sun Y et al (2022b) Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer 10:e004291","DOI":"10.1136\/jitc-2021-004291"},{"key":"413_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25202-5","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu W, Xie L, He YH, Wu ZY, Liu LX, Bai XF, Deng DX, Xu XE, Liao LD, Lin W et al (2021a) Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. Nat Commun 12:4961","journal-title":"Nat Commun"},{"key":"413_CR55","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1016\/j.molcel.2021.07.021","volume":"81","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liu Y, Qian L, Jiang S, Gai X, Ye S, Chen Y, Wang X, Zhai L, Xu J et al (2021b) A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol Cell 81:4076\u20134090.e4078","journal-title":"Mol Cell"},{"key":"413_CR56","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhang Y, Ma N, Yang Y, Ma Y, Wang F, Wang Y, Wei J, Chen H, Tartarone A et al (2023) Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell 41:1852\u20131870.e1859","journal-title":"Cancer Cell"},{"key":"413_CR57","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"HY Luo","year":"2021","unstructured":"Luo HY, Lu J, Bai YX, Mao T, Wang J, Fan QX, Zhang YP, Zhao KL, Chen ZD, Gao SG et al (2021) Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326:916\u2013925","journal-title":"JAMA"},{"key":"413_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101078","volume":"4","author":"W Luo","year":"2023","unstructured":"Luo W, Zeng Z, Jin Y, Yang L, Fan T, Wang Z, Pan Y, Yang Y, Yao M, Li Y et al (2023) Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers. Cell Rep Med 4:101078","journal-title":"Cell Rep Med"},{"key":"413_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47835-y","volume":"15","author":"J Lyu","year":"2024","unstructured":"Lyu J, Bai L, Li Y, Wang X, Xu Z, Ji T, Yang H, Song Z, Wang Z, Shang Y et al (2024) Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy. Nat Commun 15:3860","journal-title":"Nat Commun"},{"key":"413_CR60","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma J, Chen T, Wu SF, Yang CY, Bai MZ, Shu KX, Li KL, Zhang GQ, Jin Z, He FC et al (2019) iProX: an integrated proteome resource. Nucleic Acids Res 47:D1211\u2013D1217","journal-title":"Nucleic Acids Res"},{"key":"413_CR61","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel IIIEE, Koeppen H, Astarita JL, Cubas R et al (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544\u2013548","journal-title":"Nature"},{"key":"413_CR62","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cell.2016.03.031","volume":"165","author":"AJ Minn","year":"2016","unstructured":"Minn AJ, Wherry EJ (2016) Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 165:272\u2013275","journal-title":"Cell"},{"key":"413_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16017","volume":"8","author":"N Miyamura","year":"2017","unstructured":"Miyamura N, Hata S, Itoh T, Tanaka M, Nishio M, Itoh M, Ogawa Y, Terai S, Sakaida I, Suzuki A et al (2017) YAP determines the cell fate of injured mouse hepatocytes in vivo. Nat Commun 8:16017","journal-title":"Nat Commun"},{"key":"413_CR64","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1172\/JCI0215324","volume":"110","author":"OG Opitz","year":"2002","unstructured":"Opitz OG, Harada H, Suliman Y, Rhoades B, Sharpless NE, Kent R, Kopelovich L, Nakagawa H, Rustgi AK (2002) A mouse model of human oral-esophageal cancer. J Clin Invest 110:761\u2013769","journal-title":"J Clin Invest"},{"key":"413_CR65","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P et al (2018) A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359:770\u2013775","journal-title":"Science"},{"key":"413_CR66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41392-022-00946-8","volume":"7","author":"X Pan","year":"2022","unstructured":"Pan X, Wang J, Guo L, Na F, Du J, Chen X, Zhong A, Zhao L, Zhang L, Zhang M et al (2022) Identifying a confused cell identity for esophageal squamous cell carcinoma. Signal Transduct Target Ther 7:122","journal-title":"Signal Transduct Target Ther"},{"key":"413_CR67","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","volume":"24","author":"MD Park","year":"2023","unstructured":"Park MD, Reyes-Torres I, LeBerichel J, Hamon P, LaMarche NM, Hegde S, Belabed M, Troncoso L, Grout JA, Magen A et al (2023) TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat Immunol 24:792\u2013801","journal-title":"Nat Immunol"},{"key":"413_CR68","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet 381:400\u2013412","journal-title":"Lancet"},{"key":"413_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adt0214","volume":"17","author":"Z Qin","year":"2025","unstructured":"Qin Z, Jiang D, Yu Z, Li L, Xu W, Xu C, Song Q, Sun X, Li L, Guo W et al (2025) Proteogenomic characterization reveals that lipid droplet formation promotes esophageal squamous cell cancer progression. Sci Transl Med 17:eadt0214","journal-title":"Sci Transl Med"},{"key":"413_CR70","doi-asserted-by":"crossref","unstructured":"Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, Paulos CM, Rubinstein MP, Garrett-Mayer E, Hennig M et al (2017) Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis. Sci Immunol 2:eaai7911","DOI":"10.1126\/sciimmunol.aai7911"},{"key":"413_CR71","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, Strang E, Kull M, Grunschlager F, Kruger J et al (2024) The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer 5:1267\u20131284","journal-title":"Nat Cancer"},{"key":"413_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44466-7","volume":"15","author":"W Ren","year":"2024","unstructured":"Ren W, Xu Z, Chang Y, Ju F, Wu H, Liang Z, Zhao M, Wang N, Lin Y, Xu C et al (2024) Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1. Nat Commun 15:9","journal-title":"Nat Commun"},{"key":"413_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma 12:77","journal-title":"BMC Bioinforma"},{"key":"413_CR74","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature10098","volume":"473","author":"B Schwanhausser","year":"2011","unstructured":"Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M (2011) Global quantification of mammalian gene expression control. Nature 473:337\u2013342","journal-title":"Nature"},{"key":"413_CR75","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M et al (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol 17:1590\u20131598","journal-title":"Lancet Oncol"},{"key":"413_CR76","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362:k3529","journal-title":"BMJ"},{"key":"413_CR77","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1158\/1535-7163.MCT-17-0560","volume":"17","author":"S Song","year":"2018","unstructured":"Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, Skinner HD, Johnson RL, Ding S, Ajani JA (2018) A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol Cancer Ther 17:443\u2013454","journal-title":"Mol Cancer Ther"},{"key":"413_CR78","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1074\/mcp.M800518-MCP200","volume":"8","author":"RW Sprung Jr","year":"2009","unstructured":"Sprung RW Jr, Brock JW, Tanksley JP, Li M, Washington MK, Slebos RJ, Liebler DC (2009) Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteom 8:1988\u20131998","journal-title":"Mol Cell Proteom"},{"key":"413_CR79","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545\u201315550","journal-title":"Proc Natl Acad Sci USA"},{"key":"413_CR80","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398:759\u2013771","journal-title":"Lancet"},{"key":"413_CR81","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 71:209\u2013249","journal-title":"CA: A Cancer J Clin"},{"key":"413_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53826-w","volume":"15","author":"C Tang","year":"2024","unstructured":"Tang C, Wang Z, Xie Y, Fei Y, Luo J, Wang C, Ying Y, He P, Yan R, Chen Y et al (2024) Classification of distinct tendinopathy subtypes for precision therapeutics. Nat Commun 15:9460","journal-title":"Nat Commun"},{"key":"413_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26289-6","volume":"12","author":"MC Tanzer","year":"2021","unstructured":"Tanzer MC, Bludau I, Stafford CA, Hornung V, Mann M (2021) Phosphoproteome profiling uncovers a key role for CDKs in TNF signaling. Nat Commun 12:6053","journal-title":"Nat Commun"},{"key":"413_CR84","doi-asserted-by":"crossref","unstructured":"Tao C, Huang K, Shi J, Hu Q, Li K, Zhu X (2020) Genomics and prognosis analysis of epithelial-mesenchymal transition in glioma. Front Oncol 10:183","DOI":"10.3389\/fonc.2020.00183"},{"key":"413_CR85","doi-asserted-by":"publisher","first-page":"e96801","DOI":"10.1371\/journal.pone.0096801","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R, De A (2014) IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE 9:e96801","journal-title":"PLoS ONE"},{"key":"413_CR86","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20:651\u2013668","journal-title":"Nat Rev Immunol"},{"key":"413_CR87","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ccell.2025.03.003","volume":"43","author":"C Weller","year":"2025","unstructured":"Weller C, Bartok O, McGinnis CS, Palashati H, Chang TG, Malko D, Shmueli MD, Nagao A, Hayoun D, Murayama A et al (2025) Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell 43:823\u2013840.e818","journal-title":"Cancer Cell"},{"key":"413_CR88","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26:1572\u20131573","journal-title":"Bioinformatics"},{"key":"413_CR89","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2020.05.043","volume":"182","author":"JY Xu","year":"2020","unstructured":"Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, Qian K, Sun C, Liu Z, Jiang S et al (2020) Integrative proteomic characterization of human lung adenocarcinoma. Cell 182:245\u2013261.e217","journal-title":"Cell"},{"key":"413_CR90","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-022-01291-7","volume":"15","author":"N Xu","year":"2022","unstructured":"Xu N, Yao Z, Shang G, Ye D, Wang H, Zhang H, Qu Y, Xu F, Wang Y, Qin Z et al (2022) Integrated proteogenomic characterization of urothelial carcinoma of the bladder. J Hematol Oncol 15:76","journal-title":"J Hematol Oncol"},{"key":"413_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106680","volume":"103","author":"X Yan","year":"2022","unstructured":"Yan X, Duan H, Ni Y, Zhou Y, Wang X, Qi H, Gong L, Liu H, Tian F, Lu Q et al (2022) Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE). Int J Surg 103:106680","journal-title":"Int J Surg"},{"key":"413_CR92","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","volume":"42","author":"H Yang","year":"2024","unstructured":"Yang H, Cheng J, Zhuang H, Xu H, Wang Y, Zhang T, Yang Y, Qian H, Lu Y, Han F et al (2024) Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell 42:535\u2013551.e538","journal-title":"Cancer Cell"},{"key":"413_CR93","doi-asserted-by":"crossref","unstructured":"Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X et al (2022) Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer 10:e003497","DOI":"10.1136\/jitc-2021-003497"},{"key":"413_CR94","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377:2500\u20132501","journal-title":"N Engl J Med"},{"key":"413_CR95","doi-asserted-by":"crossref","unstructured":"Yin J, Yuan J, Li Y, Fang Y, Wang R, Jiao H, Tang H, Zhang S, Lin S, Su F et al (2023) Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. Nat Med 29:2068\u20132078","DOI":"10.1038\/s41591-023-02469-3"},{"key":"413_CR96","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s42255-025-01249-2","volume":"7","author":"T Yoneshiro","year":"2025","unstructured":"Yoneshiro T, Matsushita M, Fuse-Hamaoka S, Kuroiwa M, Kurosawa Y, Yamada Y, Arai M, Wei Y, Iida M, Kuma K et al (2025) Pre-fertilization-origin preservation of brown fat-mediated energy expenditure in humans. Nat Metab 7:778\u2013791","journal-title":"Nat Metab"},{"key":"413_CR97","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","volume":"29","author":"F Zanconato","year":"2016","unstructured":"Zanconato F, Cordenonsi M, Piccolo S (2016) YAP\/TAZ at the roots of cancer. Cancer Cell 29:783\u2013803","journal-title":"Cancer Cell"},{"key":"413_CR98","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","volume":"43","author":"J Zhang","year":"2022","unstructured":"Zhang J, Huang D, Saw PE, Song E (2022) Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol 43:523\u2013545","journal-title":"Trends Immunol"},{"key":"413_CR99","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1101\/gad.1602907","volume":"21","author":"B Zhao","year":"2007","unstructured":"Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L et al (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747\u20132761","journal-title":"Genes Dev"},{"key":"413_CR100","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.2023.41.16_suppl.4049","volume":"41","author":"J Zhao","year":"2023","unstructured":"Zhao J, Yang Z, Li N, Wang J, Yuan S, Wang Y, Li S, Ran F, Ji Y, Zhang Y et al (2023) Effectiveness and safety of camrelizumab in advanced esophageal cancer: a prospective multicenter observational cohort studies (ESCORT-RWS). J Clin Oncol 41:4049","journal-title":"J Clin Oncol"},{"key":"413_CR101","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ccell.2022.10.012","volume":"40","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Chen MM, Luo Y, Mojumdar K, Peng X, Chen H, Kumar SV, Akbani R, Lu Y, Liang H (2022) Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. Cancer Cell 40:1324\u20131340.e1328","journal-title":"Cancer Cell"},{"key":"413_CR102","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41551-021-00805-x","volume":"5","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Van der Jeught K, Fang Y, Yu T, Li Y, Ao Z, Liu S, Zhang L, Yang Y, Eyvani H et al (2021) An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng 5:1320\u20131335","journal-title":"Nat Biomed Eng"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00413-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00413-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00413-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:45:01Z","timestamp":1779065101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00413-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":102,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,15]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00413-9","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}